Brian K. Kaspar
Corporate Officer/Principal chez The Ohio State University College of Medicine
Postes actifs de Brian K. Kaspar
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| The Ohio State University College of Medicine | Corporate Officer/Principal | - | - |
Historique de carrière de Brian K. Kaspar
Anciens postes connus de Brian K. Kaspar
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| AVEXIS INC | Directeur/Membre du Conseil | - | 01/05/2019 |
| Directeur Technique/Scientifique/R&D | - | 01/05/2019 | |
Milo Biotechnology LLC
 Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Fondateur | 01/01/2012 | - |
Formation de Brian K. Kaspar
| University of California San Diego | Doctorate Degree |
| University of Illinois | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Founder | 1 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Milo Biotechnology LLC
Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
- Bourse
- Insiders
- Brian K. Kaspar
- Expérience
